BRIEF-Cardiff Oncology Announces Positive Initial Data From First-Line RAS-mutated mCRC Clinical Trial

Reuters12-10

Dec 10 (Reuters) - Cardiff Oncology Inc :

* CARDIFF ONCOLOGY ANNOUNCES POSITIVE INITIAL DATA FROM FIRST-LINE RAS-MUTATED MCRC CLINICAL TRIAL

* CARDIFF ONCOLOGY INC - ONVANSERTIB WELL TOLERATED AT BOTH DOSES

* CARDIFF ONCOLOGY INC - ADDITIONAL CLINICAL DATA FROM CRDF-004 TRIAL EXPECTED IN 1H 2025

Source text: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2490095036?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-10 19:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2490095036","market":"us","top_or_hot":-1,"title":"BRIEF-Cardiff Oncology Announces Positive Initial Data From First-Line RAS-mutated mCRC Clinical Trial","media":"Reuters","content":"<html><body><p>Dec 10 (Reuters) - Cardiff Oncology Inc   :</p><p>   * CARDIFF ONCOLOGY ANNOUNCES POSITIVE INITIAL DATA FROM FIRST-LINE RAS-MUTATED MCRC CLINICAL TRIAL</p><p>   * CARDIFF ONCOLOGY INC - ONVANSERTIB WELL TOLERATED AT BOTH DOSES</p><p>   * CARDIFF ONCOLOGY INC - ADDITIONAL CLINICAL DATA FROM CRDF-004 TRIAL EXPECTED IN 1H 2025</p><p>Source text:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Cardiff Oncology Announces Positive Initial Data From First-Line RAS-mutated mCRC Clinical Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Cardiff Oncology Announces Positive Initial Data From First-Line RAS-mutated mCRC Clinical Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-10 19:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Dec 10 (Reuters) - Cardiff Oncology Inc   :   * CARDIFF ONCOLOGY ANNOUNCES POSITIVE INITIAL DATA FROM FIRST-LINE RAS-MUTATED MCRC CLINICAL TRIAL   * CARDIFF ONCOLOGY INC - ONVANSERTIB WELL TOLERATED ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CRDF","symbol_name":"Cardiff Oncology, Inc.","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2490095036","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490095036","pubTimestamp":1733829236,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Dec 10  - Cardiff Oncology Inc   :   * CARDIFF ONCOLOGY ANNOUNCES POSITIVE INITIAL DATA FROM FIRST-LINE RAS-MUTATED MCRC CLINICAL TRIAL   * CARDIFF ONCOLOGY INC - ONVANSERTIB WELL TOLERATED AT BOTH DOSES   * CARDIFF ONCOLOGY INC - ADDITIONAL CLINICAL DATA FROM CRDF-004 TRIAL EXPECTED IN 1H 2025Source text:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CRDF":"Cardiff Oncology, Inc.","BK4139":"生物科技"},"translate_title":"BRIEF-Cardiff Oncology宣布一线RAS突变mCRC临床试验的积极初始数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRDF":0.9},"content_text":"Dec 10 (Reuters) - Cardiff Oncology Inc   :   * CARDIFF ONCOLOGY ANNOUNCES POSITIVE INITIAL DATA FROM FIRST-LINE RAS-MUTATED MCRC CLINICAL TRIAL   * CARDIFF ONCOLOGY INC - ONVANSERTIB WELL TOLERATED AT BOTH DOSES   * CARDIFF ONCOLOGY INC - ADDITIONAL CLINICAL DATA FROM CRDF-004 TRIAL EXPECTED IN 1H 2025Source text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490095036"}